New strategy to fight kidney cancer when first treatment fails
NCT ID NCT05931393
Summary
This study is testing if giving a higher dose of the drug cabozantinib can help control advanced kidney cancer in patients whose cancer has started growing again while on the standard dose. The trial will enroll 18 adults with advanced kidney cancer who previously benefited from cabozantinib for at least 6 months. Researchers want to see if increasing the drug dose can slow cancer progression and extend survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Conditions
Explore the condition pages connected to this study.